| Donald Alfred Ruf, MD | |
|
1000 Medical Center Blvd, Lawrenceville, GA 30045-7694 | |
| (678) 442-3317 | |
| (678) 442-4416 |
| Full Name | Donald Alfred Ruf |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1000 Medical Center Blvd, Lawrenceville, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053444356 | NPI | - | NPPES |
| 00584658A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 037061 (Georgia) | Primary |
| Entity Name | Gwinnett Hospital System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952340994 PECOS PAC ID: 8123916426 Enrollment ID: O20040309000009 |
News Archive
After Hurricane Sandy's flood waters have receded and homes demolished by the storm repaired, the unseen aftershocks of the storm may linger for many children who were in the storm's path, particularly those whose families suffered significant losses.
Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
The use of electrodes placed inside the brains of laboratory specimens has pushed the field of neuroscience to new findings for decades.
› Verified 9 days ago
| Entity Name | Northside Emergency Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285686303 PECOS PAC ID: 9335135144 Enrollment ID: O20040426000165 |
News Archive
After Hurricane Sandy's flood waters have receded and homes demolished by the storm repaired, the unseen aftershocks of the storm may linger for many children who were in the storm's path, particularly those whose families suffered significant losses.
Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
The use of electrodes placed inside the brains of laboratory specimens has pushed the field of neuroscience to new findings for decades.
› Verified 9 days ago
| Entity Name | Gwinnett Emergency Specialists Observation Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720373129 PECOS PAC ID: 7618140955 Enrollment ID: O20111101000364 |
News Archive
After Hurricane Sandy's flood waters have receded and homes demolished by the storm repaired, the unseen aftershocks of the storm may linger for many children who were in the storm's path, particularly those whose families suffered significant losses.
Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
The use of electrodes placed inside the brains of laboratory specimens has pushed the field of neuroscience to new findings for decades.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald Alfred Ruf, MD 9185 Mainsail Dr, Gainesville, GA 30506-6329 Ph: (678) 442-3317 | Donald Alfred Ruf, MD 1000 Medical Center Blvd, Lawrenceville, GA 30045-7694 Ph: (678) 442-3317 |
News Archive
After Hurricane Sandy's flood waters have receded and homes demolished by the storm repaired, the unseen aftershocks of the storm may linger for many children who were in the storm's path, particularly those whose families suffered significant losses.
Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
The use of electrodes placed inside the brains of laboratory specimens has pushed the field of neuroscience to new findings for decades.
› Verified 9 days ago
Amanarh Albert Kisseih, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30045 Phone: 678-442-3317 Fax: 678-442-4416 | |
Dr. Anna Carolyn Nay, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 Medical Center Blvd Ste 135, Lawrenceville, GA 30046 Phone: 678-312-3317 | |
Roy Gilbreath, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1185 Rivershyre Pkwy, Lawrenceville, GA 30043 Phone: 678-591-7640 | |
Tiffany Mckinnie, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30046 Phone: 678-312-4416 | |
Danielle Hines, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30046 Phone: 678-312-3317 | |
Dr. James Lofton Smith Jr., M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30045 Phone: 678-442-3317 Fax: 678-442-4416 |